Comparing Collegium Pharmaceutical (NASDAQ:COLL) and CV Sciences (OTCMKTS:CVSI)

Collegium Pharmaceutical (NASDAQ:COLL) and CV Sciences (OTCMKTS:CVSI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, profitability, analyst recommendations, institutional ownership and valuation.

Earnings & Valuation

This table compares Collegium Pharmaceutical and CV Sciences”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$631.45 million	1.63	$69.19 million	$1.22	26.23
CV Sciences	$15.70 million	0.43	-$2.39 million	N/A	N/A

Collegium Pharmaceutical has higher revenue and earnings than CV Sciences.

Profitability

This table compares Collegium Pharmaceutical and CV Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	6.61%	99.08%	15.14%
CV Sciences	-12.25%	-89.43%	-22.75%

Risk and Volatility

Collegium Pharmaceutical has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Comparatively, CV Sciences has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Collegium Pharmaceutical and CV Sciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	0	1	3	0	2.75
CV Sciences	0	0	0	0	0.00

Collegium Pharmaceutical presently has a consensus target price of $43.75, indicating a potential upside of 36.72%. Given Collegium Pharmaceutical’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Collegium Pharmaceutical is more favorable than CV Sciences.

Summary

Collegium Pharmaceutical beats CV Sciences on 10 of the 10 factors compared between the two stocks.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

About CV Sciences

CV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The company offers its products under the PlusCBD, ProCBD, HappyLane, CVAcute, CVDefense, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, elect distributors, brick and mortar retailers, and select e-tailers. It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.